Overview

A Study of OLP-1002 Subcutaneous Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in a Hip and/or Knee Joint

Status:
Recruiting

Trial end date:
2023-09-30

Target enrollment:

Participant gender:

Summary

The study is designed to evaluate the efficacy, safety and tolerability of OLP-1002 Subcutaneous (SC) injections for reducing moderate to severe pain due to osteoarthritis in a hip and/or knee joint.

Phase:

Phase 2

Details

Lead Sponsor:

OliPass Corporation

Collaborator:

Novotech (Australia) Pty Limited